Market Cap 616.93M
Revenue (ttm) 0.00
Net Income (ttm) -38.18M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.34
Volume 2,853,500
Avg Vol 1,832,774
Day's Range N/A - N/A
Shares Out 73.27M
Stochastic %K 61%
Beta -0.49
Analysts Strong Sell
Price Target $19.12

Company Profile

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic,...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 916 5445
Address:
117 Kendrick Street, Suite 450, Needham, United States
PatSoonDiggler
PatSoonDiggler Jun. 5 at 12:41 AM
$CADL Diggs is ready for CADL to shoot … to the Moon! https://x.com/RealEmirHan/status/2062669918948987238/video/1?s=46
0 · Reply
Chetlay
Chetlay Jun. 5 at 12:22 AM
$CADL 💯
0 · Reply
VictoriaCapital
VictoriaCapital Jun. 5 at 12:03 AM
$CADL Not sure I’ve ever seen a company being built for value creation in such a systematic way, grounded in world-class science, operational excellence, disciplined capital allocation, and the nimbleness to adapt as opportunities emerge. Great companies don’t happen by accident. They are built through thousands of thoughtful decisions, executed consistently over time.
4 · Reply
graywolf
graywolf Jun. 4 at 11:48 PM
$CADL Even a $10B buyout seems cheap given the potential of the assets the company is holding/developing!
1 · Reply
telomerase
telomerase Jun. 4 at 11:31 PM
$CADL There have been a lot of comments today that sound like they're from people that have never met a HEK293. Well, I knew JEK293, and you sirs, are no JEK293. First thing to remember is that the start of adenoviral production is with a manufactured plasmid. Unless you're a moron that hasn't backed up your hard drive for 10 years (and if you're reading this in France, you know who you are), you should have the DNA sequence of the plasmid recorded in multiple places. So even if your original lab were to be hit by a relativistic impactor and turned to plasma, that sequence should still be in the cloud somewhere and also tattooed onto your back (adenoviruses are only ~36,000 characters long). And that DNA sequence is what determines what comes out of the HEK293 cells, even if it's a decade later. The CMC isn't going to have any trouble making a functional equivalent of the original garage batch of CAN-2409. https://blog.addgene.org/adenoviral-vector-production-and-troubleshooting
1 · Reply
drizz
drizz Jun. 4 at 11:27 PM
$CADL I think things could get wild here as shorts are clearly trapped w the OS now just about locked up and the float shrinking literally by the day - initiation of ph 3 nsclc could be the spark that ignites the powder keg!!! I estimate just 4 M of float - that was before this weeks jefferies conference - I’m guessing many tutes were wiping the druel from thier chins as they heard about the opp Cadl now represents - just 4 months from BLA Submission and initiation of nsclc any day!!! Could be the spark to get us to the mid teens which is still absurdly cheap for this pipeline! We got a fun 12-18 months ahead of us folks!!!
1 · Reply
CO145
CO145 Jun. 4 at 11:15 PM
$CADL Starting a Phase 3 trial does not guarantee comparability success, but it would be unusual for a management team to launch a study if they believed there was a material chance the manufacturing package would fail.
0 · Reply
CO145
CO145 Jun. 4 at 11:15 PM
$CADL Normally the start of a P3 trial is not newsworthy or stock moving. However, since CMC is the remaining issue, starting the P3 pivotal trial may actually be an important milestone and add to valuation as it suggests mgmt is very comfortable with comparability between completed Batch 1 and its ongoing mfg of Batch 2. It is quite nuanced that most will overlook. Perhaps some sell side analyst will be smart enough to realize the importance and write about it. If management starts a pivotal Phase 3 trial while Batch 2 comparability work is ongoing: Management already has substantial internal data suggesting comparability will be successful. The remaining work is confirmatory rather than exploratory. The regulatory feedback received to date has been supportive enough that the company is comfortable committing significant capital to the trial.
0 · Reply
Drcando
Drcando Jun. 4 at 10:57 PM
$CADL Think about these realistic high numbers an you will feel the excitement of almost all Of us 🚀🚀🚀🐂🐂🐂🏦🏦🏦🔜🔜🔜
2 · Reply
TheBigM
TheBigM Jun. 4 at 10:27 PM
$CADL wooooo CADL baby CADL baby CADL
0 · Reply
Latest News on CADL
Candel Therapeutics price target raised to $9 from $7 at BofA

2026-05-18T19:30:09.000Z - 17 days ago

Candel Therapeutics price target raised to $9 from $7 at BofA


Candel Therapeutics Transcript: Study result

May 15, 2026, 1:00 PM EDT - 20 days ago

Candel Therapeutics Transcript: Study result


Candel Therapeutics Slides: Study result

May 15, 2026, 1:00 PM EDT - 20 days ago

Candel Therapeutics Slides: Study result


Candel Therapeutics Press release: Study result

May 15, 2026, 1:00 PM EDT - 20 days ago

Candel Therapeutics Press release: Study result


Candel Therapeutics Earnings release: Q1 2026

May 14, 2026, 8:00 AM EDT - 21 days ago

Candel Therapeutics Earnings release: Q1 2026


Candel Therapeutics Quarterly report: Q1 2026

May 14, 2026, 8:00 AM EDT - 21 days ago

Candel Therapeutics Quarterly report: Q1 2026


Candel Therapeutics Slides: Corporate presentation

May 14, 2026, 7:00 AM EDT - 21 days ago

Candel Therapeutics Slides: Corporate presentation


Candel Therapeutics to Present at Upcoming Investor Conferences

May 13, 2026, 8:05 AM EDT - 22 days ago

Candel Therapeutics to Present at Upcoming Investor Conferences


Candel Therapeutics Slides: Corporate presentation

May 13, 2026, 7:00 AM EDT - 22 days ago

Candel Therapeutics Slides: Corporate presentation


Candel Therapeutics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 5 weeks ago

Candel Therapeutics Proxy statement: Proxy filing


Candel Therapeutics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 5 weeks ago

Candel Therapeutics Proxy statement: Proxy filing


Candel Therapeutics Slides: Corporate presentation

Apr 14, 2026, 7:00 AM EDT - 7 weeks ago

Candel Therapeutics Slides: Corporate presentation


Candel Therapeutics price target raised to $26 from $22 at Citi

2026-03-18T10:22:07.000Z - 2 months ago

Candel Therapeutics price target raised to $26 from $22 at Citi


Candel Therapeutics Slides: Corporate presentation

Mar 17, 2026, 7:00 AM EDT - 2 months ago

Candel Therapeutics Slides: Corporate presentation


Candel Therapeutics reports Q4 EPS (54c) vs. (40c) last year

2026-03-12T12:11:41.000Z - 3 months ago

Candel Therapeutics reports Q4 EPS (54c) vs. (40c) last year


Candel Therapeutics sees cash runway into 1Q28

2026-03-12T12:11:01.000Z - 3 months ago

Candel Therapeutics sees cash runway into 1Q28


Candel Therapeutics Earnings release: Q4 2025

Mar 12, 2026, 7:00 AM EDT - 3 months ago

Candel Therapeutics Earnings release: Q4 2025


Candel Therapeutics Annual report: Q4 2025

Mar 12, 2026, 7:00 AM EDT - 3 months ago

Candel Therapeutics Annual report: Q4 2025


Candel Therapeutics 18.3M share Spot Secondary priced at $5.45

2026-02-20T03:25:29.000Z - 3 months ago

Candel Therapeutics 18.3M share Spot Secondary priced at $5.45


Candel Therapeutics 18.3M share Spot Secondary priced at $5.45

2026-02-20T03:25:12.000Z - 3 months ago

Candel Therapeutics 18.3M share Spot Secondary priced at $5.45


Candel Therapeutics Announces Pricing of Public Offering

Feb 19, 2026, 9:40 PM EST - 3 months ago

Candel Therapeutics Announces Pricing of Public Offering


Candel Therapeutics announces $100M royalty funding agreement

2026-02-19T22:10:17.000Z - 3 months ago

Candel Therapeutics announces $100M royalty funding agreement


Candel Therapeutics announces $100M common stock offering

2026-02-19T21:13:42.000Z - 3 months ago

Candel Therapeutics announces $100M common stock offering


Candel Therapeutics Slides: Corporate Presentation

Dec 10, 2025, 7:00 AM EST - 6 months ago

Candel Therapeutics Slides: Corporate Presentation


Candel Therapeutics Transcript: R&D Day 2025

Dec 5, 2025, 11:00 AM EST - 6 months ago

Candel Therapeutics Transcript: R&D Day 2025


Candel Therapeutics Press release: FY 2025

Dec 5, 2025, 11:00 AM EST - 6 months ago

Candel Therapeutics Press release: FY 2025


Candel Therapeutics reports Q3 EPS (21c) vs (33c) last year

2025-11-13T13:31:40.000Z - 7 months ago

Candel Therapeutics reports Q3 EPS (21c) vs (33c) last year


Candel Therapeutics Quarterly report: Q3 2025

Nov 13, 2025, 8:00 AM EST - 7 months ago

Candel Therapeutics Quarterly report: Q3 2025


Candel Therapeutics Earnings release: Q3 2025

Nov 13, 2025, 8:00 AM EST - 7 months ago

Candel Therapeutics Earnings release: Q3 2025


Candel Therapeutics Slides: Corporate Presentation

Nov 12, 2025, 7:00 AM EST - 7 months ago

Candel Therapeutics Slides: Corporate Presentation


Candel Therapeutics initiated with an Overweight at Stephens

2025-10-27T20:35:14.000Z - 7 months ago

Candel Therapeutics initiated with an Overweight at Stephens


Candel Therapeutics appoints Pulendran to Candel’s RAB

2025-10-16T12:20:35.000Z - 8 months ago

Candel Therapeutics appoints Pulendran to Candel’s RAB


Candel Therapeutics enters into $130M term loan facility

2025-10-14T12:31:44.000Z - 8 months ago

Candel Therapeutics enters into $130M term loan facility

TRIN


Candel Therapeutics to Present at the SITC 2025 Annual Meeting

Oct 3, 2025, 9:05 AM EDT - 8 months ago

Candel Therapeutics to Present at the SITC 2025 Annual Meeting


Candel Therapeutics Quarterly report: Q2 2025

Aug 14, 2025, 8:00 AM EDT - 10 months ago

Candel Therapeutics Quarterly report: Q2 2025


Candel Therapeutics Earnings release: Q2 2025

Aug 14, 2025, 8:00 AM EDT - 10 months ago

Candel Therapeutics Earnings release: Q2 2025


Candel Therapeutics Registration statement: Registration Filing

Aug 14, 2025, 8:00 AM EDT - 10 months ago

Candel Therapeutics Registration statement: Registration Filing


Candel Therapeutics Quarterly report: Q1 2025

May 13, 2025, 8:00 AM EDT - 1 year ago

Candel Therapeutics Quarterly report: Q1 2025


Candel Therapeutics Earnings release: Q1 2025

May 13, 2025, 8:00 AM EDT - 1 year ago

Candel Therapeutics Earnings release: Q1 2025


Candel Therapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Candel Therapeutics Proxy statement: Proxy Filing


Candel Therapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Candel Therapeutics Proxy statement: Proxy Filing


Candel Therapeutics Annual report: Q4 2024

Mar 13, 2025, 9:30 AM EDT - 1 year ago

Candel Therapeutics Annual report: Q4 2024


Candel Therapeutics Earnings release: Q4 2024

Mar 13, 2025, 9:30 AM EDT - 1 year ago

Candel Therapeutics Earnings release: Q4 2024


Candel Therapeutics Transcript: Study Result

Dec 11, 2024, 8:30 AM EST - 1 year ago

Candel Therapeutics Transcript: Study Result


Candel Therapeutics Press release: Study Result

Dec 11, 2024, 8:30 AM EST - 1 year ago

Candel Therapeutics Press release: Study Result


Candel Therapeutics' cancer drug meets late-stage trial goals

Dec 11, 2024, 7:09 AM EST - 1 year ago

Candel Therapeutics' cancer drug meets late-stage trial goals


PatSoonDiggler
PatSoonDiggler Jun. 5 at 12:41 AM
$CADL Diggs is ready for CADL to shoot … to the Moon! https://x.com/RealEmirHan/status/2062669918948987238/video/1?s=46
0 · Reply
Chetlay
Chetlay Jun. 5 at 12:22 AM
$CADL 💯
0 · Reply
VictoriaCapital
VictoriaCapital Jun. 5 at 12:03 AM
$CADL Not sure I’ve ever seen a company being built for value creation in such a systematic way, grounded in world-class science, operational excellence, disciplined capital allocation, and the nimbleness to adapt as opportunities emerge. Great companies don’t happen by accident. They are built through thousands of thoughtful decisions, executed consistently over time.
4 · Reply
graywolf
graywolf Jun. 4 at 11:48 PM
$CADL Even a $10B buyout seems cheap given the potential of the assets the company is holding/developing!
1 · Reply
telomerase
telomerase Jun. 4 at 11:31 PM
$CADL There have been a lot of comments today that sound like they're from people that have never met a HEK293. Well, I knew JEK293, and you sirs, are no JEK293. First thing to remember is that the start of adenoviral production is with a manufactured plasmid. Unless you're a moron that hasn't backed up your hard drive for 10 years (and if you're reading this in France, you know who you are), you should have the DNA sequence of the plasmid recorded in multiple places. So even if your original lab were to be hit by a relativistic impactor and turned to plasma, that sequence should still be in the cloud somewhere and also tattooed onto your back (adenoviruses are only ~36,000 characters long). And that DNA sequence is what determines what comes out of the HEK293 cells, even if it's a decade later. The CMC isn't going to have any trouble making a functional equivalent of the original garage batch of CAN-2409. https://blog.addgene.org/adenoviral-vector-production-and-troubleshooting
1 · Reply
drizz
drizz Jun. 4 at 11:27 PM
$CADL I think things could get wild here as shorts are clearly trapped w the OS now just about locked up and the float shrinking literally by the day - initiation of ph 3 nsclc could be the spark that ignites the powder keg!!! I estimate just 4 M of float - that was before this weeks jefferies conference - I’m guessing many tutes were wiping the druel from thier chins as they heard about the opp Cadl now represents - just 4 months from BLA Submission and initiation of nsclc any day!!! Could be the spark to get us to the mid teens which is still absurdly cheap for this pipeline! We got a fun 12-18 months ahead of us folks!!!
1 · Reply
CO145
CO145 Jun. 4 at 11:15 PM
$CADL Starting a Phase 3 trial does not guarantee comparability success, but it would be unusual for a management team to launch a study if they believed there was a material chance the manufacturing package would fail.
0 · Reply
CO145
CO145 Jun. 4 at 11:15 PM
$CADL Normally the start of a P3 trial is not newsworthy or stock moving. However, since CMC is the remaining issue, starting the P3 pivotal trial may actually be an important milestone and add to valuation as it suggests mgmt is very comfortable with comparability between completed Batch 1 and its ongoing mfg of Batch 2. It is quite nuanced that most will overlook. Perhaps some sell side analyst will be smart enough to realize the importance and write about it. If management starts a pivotal Phase 3 trial while Batch 2 comparability work is ongoing: Management already has substantial internal data suggesting comparability will be successful. The remaining work is confirmatory rather than exploratory. The regulatory feedback received to date has been supportive enough that the company is comfortable committing significant capital to the trial.
0 · Reply
Drcando
Drcando Jun. 4 at 10:57 PM
$CADL Think about these realistic high numbers an you will feel the excitement of almost all Of us 🚀🚀🚀🐂🐂🐂🏦🏦🏦🔜🔜🔜
2 · Reply
TheBigM
TheBigM Jun. 4 at 10:27 PM
$CADL wooooo CADL baby CADL baby CADL
0 · Reply
The1Albatross
The1Albatross Jun. 4 at 10:19 PM
2 · Reply
1Loonie2Toonie
1Loonie2Toonie Jun. 4 at 10:10 PM
2 · Reply
Riskybio
Riskybio Jun. 4 at 9:53 PM
$CADL ok for the buyout hopefuls at $6+BB. We broke thru the $9.20ish resistance.. Next up the 3 Spikes around 14ish..: Get up near $30… Then you can start dreaming about $60+ buyout scenario LFG!!
2 · Reply
John_morrris
John_morrris Jun. 4 at 9:51 PM
$CADL Sharing (Memory Jogger) PRICING for Prostate Cancer Drug if approved by FDA. Watch what PPT says between 25 min and 26 minute in the video below: (On the higher end of the spectrum between 150K-250K - and the reasons he gives) https://event.summitcast.com/view/SScpdhHfwE8g9WsS8WcTax/G5DUMcZJ8nCWyyaqY4ZJmA
1 · Reply
Clemente4141
Clemente4141 Jun. 4 at 9:18 PM
$CADL from a technical perspective, the breakout point today was at $9.27, the 52 week high price. Once it rose above it needed a test of the breakout price, which is where the price sits. There may be more tests of this price. Price may fall below $9.27. Nobody really knows what will happen here. Charts for this one have been a bit crazy lately. Like somebody is controlling it?
1 · Reply
PatSoonDiggler
PatSoonDiggler Jun. 4 at 9:03 PM
$CADL If CAN-2409 ultimately became standard of care alongside radiation therapy for just the ~50,000 U.S. patients receiving radiation annually, even a $50,000 treatment price would imply a potential U.S. market of roughly $2.5 billion per year. Candel itself has publicly stated the U.S. localized prostate cancer opportunity could exceed $10 billion. LFG
1 · Reply
PatSoonDiggler
PatSoonDiggler Jun. 4 at 9:02 PM
$CADL Most investors think CADL is a small biotech chasing a niche cancer indication. In reality, CAN-2409 is aimed at one of the largest untreated opportunities in oncology: preventing recurrence in tens of thousands of newly diagnosed prostate cancer patients every year. There hasn’t been a meaningful new therapy added to the standard radiation treatment paradigm in localized prostate cancer in over 20 years.
0 · Reply
PatSoonDiggler
PatSoonDiggler Jun. 4 at 9:01 PM
$CADL Roughly 100,000+ U.S. men are diagnosed each year with localized prostate cancer that could potentially fit CAN-2409’s treatment paradigm. * About 70% of all prostate cancers are diagnosed while still localized, meaning the disease has not yet spread. * More than 50,000 men per year receive radiation therapy, which is the exact setting in which CAN-2409 demonstrated its Phase 3 benefit.
1 · Reply
Newageinvestor
Newageinvestor Jun. 4 at 8:57 PM
$CADL 400k shares traded in the last 20 minutes of the day, with a move to $9.4 on 200k shares and a final drop going in to the close on 100k shares. The pattern repeats itself. Managed to achieve the highest low of the day ($8.75) in over 5 years. Also hit an intraday 52 week high. I would view any pullback as acceptable and short term as the trend is most definitely up.
0 · Reply
Greyhound9
Greyhound9 Jun. 4 at 8:54 PM
$CADL This movement was not visible on Yahoo Finance. I follow the price there every day. There is also no delay as far as I can see.
0 · Reply
MasterOfTheUniverse15
MasterOfTheUniverse15 Jun. 4 at 8:53 PM
$CADL At this point, a double-digit share price is a mathematical certainty. In fact, CADL is positioned to breeze right past $10.00 so quickly you won't even have time to react.
0 · Reply
XQuise
XQuise Jun. 4 at 8:53 PM
$CADL the float is definitely drying slowly 🤓🤏🏻🐋
1 · Reply